These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
641 related articles for article (PubMed ID: 19024911)
1. [Drugs for antiretroviral therapy. The costs of HAART]. Jablonowski H MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911 [No Abstract] [Full Text] [Related]
2. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534 [TBL] [Abstract][Full Text] [Related]
3. [Pharmaco-economic aspects of HIV therapy. Savings with HAART]. MMW Fortschr Med; 2003 Apr; 145 Spec No 1():80. PubMed ID: 15011600 [No Abstract] [Full Text] [Related]
4. Sustaining treatment costs: who will pay? Zewdie D; De Cock K; Piot P AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744 [No Abstract] [Full Text] [Related]
5. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Krentz HB; Auld MC; Gill MJ; CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156 [TBL] [Abstract][Full Text] [Related]
6. Providing antiretroviral therapy for HIV infection. Steinbrook R N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164 [No Abstract] [Full Text] [Related]
7. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care]. Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of HIV-infections: success or crisis?]. Pokrovskiĭ VV Ter Arkh; 2001; 73(11):52-4. PubMed ID: 11806206 [No Abstract] [Full Text] [Related]
9. [Clinical and economic impact of new antiretroviral treatments]. Moreno Guillén S; Pérez Elías MJ Rev Clin Esp; 1999 Feb; 199(2):53-4. PubMed ID: 10216393 [No Abstract] [Full Text] [Related]
10. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives? Colebunders R; Florence E; Lynen L; Bouckenooghe A Int J STD AIDS; 2003 Jan; 14(1):1-5. PubMed ID: 12590784 [No Abstract] [Full Text] [Related]
11. Costs decline with HAART. AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187110 [No Abstract] [Full Text] [Related]
12. Stirring the statistical pot. Bateman C S Afr Med J; 2004 Mar; 94(3):154-5. PubMed ID: 15098266 [No Abstract] [Full Text] [Related]
13. [HIV infection and AIDS from the health policy viewpoint. Savings and therapy superiority maintained - a contradiction in HIV therapy?]. MMW Fortschr Med; 2014 Jun; 156 Suppl 1():62-3. PubMed ID: 25026863 [No Abstract] [Full Text] [Related]
14. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. Marseille E; Saba J; Muyingo S; Kahn JG AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976 [TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas? Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234 [No Abstract] [Full Text] [Related]
16. [The treatment of AIDS too expensive?]. Kutschki I Dtsch Med Wochenschr; 1998 Mar; 123(10):A12. PubMed ID: 9528643 [No Abstract] [Full Text] [Related]
17. Strategies for the scale-up of antiretroviral therapy in South Africa through health system optimization. Barker PM; McCannon CJ; Mehta N; Green C; Youngleson MS; Yarrow J; Bennett B; Berwick DM J Infect Dis; 2007 Dec; 196 Suppl 3():S457-63. PubMed ID: 18181694 [TBL] [Abstract][Full Text] [Related]
18. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241 [TBL] [Abstract][Full Text] [Related]
19. The cost of antiretroviral drugs and influence on prescribing policies. Jones R; Gazzard B Int J STD AIDS; 2006 Aug; 17(8):499-506. PubMed ID: 16925892 [TBL] [Abstract][Full Text] [Related]
20. [Antiretroviral treatment of HIV infections in poor countries]. Eskesen AN Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3255-7. PubMed ID: 14714026 [No Abstract] [Full Text] [Related] [Next] [New Search]